Source: Virtual Congress 2021 – Repair and regeneration in chronic lung disease and lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
P. Hiemstra (Leiden, Netherlands). Mesenchymal stem cell therapy for severe emphysema. Virtual Congress 2021 – Repair and regeneration in chronic lung disease and lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Mesenchymal stem cells and fibrotic lung diseases Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Mesenchymal stem cells in aging and IPF Source: ERS Research Seminar 2017 – Integrating systems biology approach in idiopathic pulmonary fibrosis research Year: 2016 Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease Source: ERS Lung Science Conference 2017 Year: 2017 Mesenchymal lineage formation in the lung during development and disease Source: International Congress 2017 – Molecular pathways in lung development Year: 2017 Mesenchymal stem cells and their potential for clinical use Source: Annual Congress 2004 - Cellular and molecular strategies to repair the damaged lung Year: 2004 Oral presentation: Mesenchymal induction of lung endoderm progenitor cells from embryonic stem cells Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Mesenchymal cells, immune cells and the lung stem cell niche Source: Eur Respir Monogr 2021; 91: 134-143 Year: 2021 Noninfectious pulmonary complications of haematopoietic stem cell transplantation Source: Eur Respir Rev, 29 (156) 190119; 10.1183/16000617.0119-2019 Year: 2020 Obliterative bronchiolitis in haematopoietic stem cell transplantation: can it be treated? Source: Eur Respir J 2005; 25: 402-405 Year: 2005 PP206 – Modeling idiopathic pulmonary fibrosis using induced pluripotent stem cell-derived alveolar epithelial organoids Source: ERS Lung Science Conference 2021 Year: 2021 Mesenchymal stem cell based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysacharride in mice Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008 Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020 Year: 2022 Induced pluripotent stem cells for generating lung airway stem cells and modelling respiratory disease Source: Eur Respir Monogr 2021; 91: 190-204 Year: 2021 Successful transplantation of rat mesenchymal stem cells, for the therapy of bleomycin induced lung injury Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Mesenchymal stem cells and recombinant erythropoietin treatment in an experimental sepsis model Source: Annual Congress 2012 - The many roads to lung injury Year: 2012 Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS Source: Virtual Congress 2020 – New insights into mechanical ventilation in the intensive care unit Year: 2020 Pulmonary interstitial glycogenosis cells express mesenchymal stem cell markers Source: Eur Respir J, 56 (4) 2000853; 10.1183/13993003.00853-2020 Year: 2020